Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis
Gene therapy company awarded grant for evaluation of ALS treatment
August 26th, 2005
Oxford BioMedica (OXB) announced that the UK Motor Neurone Disease (MND) Association has awarded a research grant to support preclinical evaluation of MoNuDin for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease. The grant is initially for UKP 350,000, which will fund a key preclinical efficacy study and support preparations for clinical trials. The company is targeting the start of clinical development in 2006-07. MoNuDin is a novel gene therapy product, which delivers a vascular endothelial growth factor (VEGF) gene, a neuroprotective factor, using the company's proprietary LentiVector...
Source: Drug Week (2005-08-26)
|
